drugset / Trial / NCT05816356
To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males
RandomizedCrossoverOpen-labelTreatment
Summary
This is an open-label, randomized, single-dose per period, two-period, crossover study to evaluate the relative bioavailability of decitabine and tetrahydrouridine ingested as a modified-release combination formulation compared to THU and decitabine ingested as immediate-release capsules
Timeline
- Start
- 2023-03-24
- Primary completion
- 2023-06-30
- Completion
- 2023-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 2.5 mg | Oral |
| Subject | Tetrahydrouridine | Small molecule | 100 mg | Oral |
Indications
No indication recorded.